

Total Pages	2
-------------	---

PATENT APPLICATION
TRANSMITTAL

Title of Invention: AN IMPROVED STENT FOR USE IN A STENT GRAFT

Name Peter A. Vasa Date November 2, 2008

Patricia A. Jara

Express Mail No.

EY
EK222051375US

APPLICATIONS UNDER 37 CFR 1.53(b)]

ADDRESS TO: Assistant Commissioner for Patents
Box – Patent Application
Washington, D.C. 20231

1.	<input checked="" type="checkbox"/>	Fee Transmittal (attached hereto in duplicate)
2.	<input checked="" type="checkbox"/>	Specification - Total Pages: 23
	<input type="checkbox"/>	Preferred arrangement set forth below:
	<input checked="" type="checkbox"/>	- Descriptive Title of the Invention
	<input checked="" type="checkbox"/>	- Cross References to Related Applications
	<input type="checkbox"/>	- Statement Regarding Fed sponsored R&D
	<input type="checkbox"/>	- Reference to Microfiche Appendix
	<input checked="" type="checkbox"/>	- Background of the Invention
	<input checked="" type="checkbox"/>	- Brief Summary of the Invention
	<input checked="" type="checkbox"/>	- Brief Description of the Drawings (if filed)
	<input checked="" type="checkbox"/>	- Detailed Description
	<input checked="" type="checkbox"/>	- Claim(s)
	<input checked="" type="checkbox"/>	- Abstract of the Disclosure
3.	<input checked="" type="checkbox"/>	Drawing(s) [35 USC 113]-Total Sheets:17 (formal)
4.		Oath or Declaration
a.	<input checked="" type="checkbox"/>	Executed (original)
b.	<input type="checkbox"/>	Copy from a prior application [37 CFR 1.63(d)] (For continuation/divisional check boxes 5 & 17.)
	i.	<input type="checkbox"/> Deletion of Inventor(s) Signed statement attached deleting inventor(s) named in the prior applica- tion, see 37 CFR 1.63(d)(2) & 1.33(b).

6. ☐ Microfiche Computer Program (Appendix)

7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☐ Paper Copy (identical to computer copy)

c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment & Recordation Form Cover Sheet

9. ☐ 37 CFR 3.73(b) Statement for
Terminal Disclaimer
(When there is an assignee.)

☐ Power of Attorney

10. ☐ English Translation Document
(if applicable)

11. ☐ Information Disclosure Statement (IDS)
and PTO-1449 (COPY)

☐ Copies of IDS Citations

12. ☐ Preliminary Amendment

13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized.)

14. ☐ Certified Copy of Priority Document(s)
(If foreign priority is claimed.)

15. ☒ Other: Application Cover Sheet
w/Express Mail Certification

16. If a CONINUING APPLICATION, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior Application No.:

17.	<input type="checkbox"/>	Amend the specification by inserting before the first line the sentence: --This is a
	<input type="checkbox"/>	Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-Part (CIP) of

18. ☒ The Commissioner is hereby authorized to charge the following fees or credit any overpayment to Deposit Account No. **10-0750**. (A duplicate copy of this sheet is enclosed.)

19. CORRESPONDENCE ADDRESS:

Name: Audley A. Ciamporcero, Jr., Esq.

Address: Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (U.S.A.)

20. TELEPHONE CONTACT:

Please direct all telephone calls or facsimiles to the attention of Bernard E. Shay at:
Telephone No. (513) 337-3231 / Facsimile No. (513) 337-8489

21. The filing fee has been calculated as shown below:

FOR:	NO. FILED	NO. EXTRA	OTHER THAN A SMALL ENTITY	
			RATE	FEE
BASIC FEE				\$ 710.00
TOTAL CLAIMS	22 - 20 =	0	X 18 =	\$ 36.00
INDEPENDENT CLAIMS	3 - 3 =	0	X 78 =	\$ 000.00
MULTIPLE DEPENDENT CLAIM PRESENTED			+ 260	\$ 000.00
			TOTAL	\$ 746.00

☐ Please Cancel Claims

☒ Please charge my Deposit Account No. 10-0750 amount of \$ **746.00**.

Two duplicate copies of this sheet is enclosed

☒ The Commissioner is hereby authorized to charge the following fees or credit any overpayment to Deposit Account No. 10-0750.


Two duplicate copies of this sheet is enclosed

☒ Any additional filing fees required under 37 CFR 1.16.

☐ Any patent application processing fees under 37 CFR 1.17. (Extension of Time and Other Petitions)

☒ Any fee for recording an assignment.

22. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED:



Dean L. Garner
Reg. No.: 35,877

November 16, 2000
Date

AN IMPROVED STENT FOR USE IN A STENT GRAFT

FIELD OF THE INVENTION

5 The invention relates to percutaneously delivered stent grafts for repairing an abdominal aortic aneurysms.

BACKGROUND OF THE INVENTION

10 An abdominal aortic aneurysm is a sac caused by an abnormal dilation of the wall of the aorta, a major artery of the body, as it passes through the abdomen. The abdomen is that portion of the body which lies between the thorax and the pelvis. It contains a cavity, known as the abdominal cavity, separated by the diaphragm from the thoracic cavity and lined with a membrane, the peritoneum. The aorta is the main
15 trunk, or artery, from which the systemic arterial system proceeds. It arises from the left ventricle of the heart, passes upward, bends over and passes down through the thorax and through the abdomen to about the level of the fourth lumbar vertebra, where it divides into the two common iliac arteries.

20 The aneurysm often arises in the infrarenal portion of the diseased aorta, for example, below the kidneys. When left untreated, the aneurysm will eventually cause rupture of the sac with ensuing fatal hemorrhaging in a very short time. High mortality associated with the rupture has led to the present state of the art and the trans-abdominal surgical repair of abdominal aortic aneurysms. Surgery involving the
25 abdominal wall, however, is a major undertaking with associated high risks. There is considerable mortality and morbidity associated with this magnitude of surgical intervention, which in essence involves replacing the diseased and aneurysmal segment of blood vessel with a prosthetic device which typically is a synthetic tube, or graft, usually fabricated of either DACRON®, TEFLON®, GORTEX®, or other
30 suitable material.

To perform the surgical procedure requires exposure of the aorta through an abdominal incision, which can extend from the rib cage to the pubis. The aorta must be cross-clamped both above and below the aneurysm, so that the aneurysm can then be opened and the thrombus, or blood clot, and arteriosclerotic debris removed.

5 Small arterial branches from the back wall of the aorta are tied off. The DACRON® tube, or graft, of approximately the same size of the normal aorta is sutured in place, thereby replacing the aneurysm. Blood flow is then reestablished through the graft. It is necessary to move the intestines in order to get to the back wall of the abdomen prior to clamping off the aorta.

10

If the surgery is performed prior to rupturing of the abdominal aortic aneurysm, the survival rate of treated patients is markedly higher than if the surgery is performed after the aneurysm ruptures, although the mortality rate is still relatively high. Although abdominal aortic aneurysms can be detected from routine
15 examinations, the patient may not experience any pain from the condition. Thus, if the patient is not receiving routine examinations, it is possible that the aneurysm will progress to the rupture stage.

Disadvantages associated with the conventional, prior art surgery, in addition
20 to the high mortality rate, are: the extended recovery period associated with the large surgical exposure in such open procedures; difficulties in suturing the graft, or tube, to the aorta; the loss of the existing thrombosis to support and reinforce the graft; the unsuitability of the surgery for many patients having abdominal aortic aneurysms; and the problems associated with performing the surgery on an emergency basis after the
25 aneurysm has ruptured. As to the extent of recovery, a patient can expect to spend from 1 to 2 weeks in the hospital after the surgery, a major portion of which is spent in the intensive care unit, and a convalescence period at home from 2 to 3 months, particularly if the patient has other illness such as heart, lung, liver, and/or kidney disease, in which case the hospital stay is also lengthened. Since the graft must be
30 secured, or sutured, to the remaining portion of the aorta, it is often difficult to perform the suturing step because of thrombosis present on the remaining portion of

the aorta, and that remaining portion of the aorta wall may be friable, or easily crumbled.

Since the thrombosis is totally removed in the prior art surgery, the new graft
5 does not have the benefit of the previously existing thrombosis therein, which could be utilized to support and reinforce the graft, were the graft to be able to be inserted within the existing thrombosis. Since many patients having abdominal aortic aneurysms have other chronic illnesses, such as heart, lung, liver, and/or kidney disease, coupled with the fact that many of these patients are older, these patients are
10 not ideal candidates for such surgery, which is considered major surgery. Such patients have difficulties in surviving the operation. Lastly, once the aneurysm has ruptured, it is difficult to perform a conventional surgery on an expedited basis because of the extent of the surgery.

Accordingly, the prior art teaches various methods and apparatuses for
15 repairing an abdominal aortic aneurysm which is believed to lower morbidity and mortality rate by not requiring an abdominal incision and general anesthesia, not requiring suturing the graft to the remaining aortic wall, and which permits the existing aortic wall and thrombosis therein to be retained to reinforce and support the
20 aortic graft. An example of such a method and apparatus is given in U.S. Patents 5,316,023 issued to Palmaz et al. on May 31, 1994; 5,360,443 issued to Barone et al. on November 1, 1994; 5,578,071 issued to Parodi on November 26, 1996; and 5,591,229 issued to Parodi on January 7, 1997, all of which are hereby incorporated herein by reference.

25

Devices, such as the one shown in the above referenced Barone patent, use an improved method for repairing an abdominal aortic aneurysm in an aorta having two iliac arteries associated therewith. The device includes first and second tubes, preferably made from a variety of materials such as DACRON® and other polyester
30 materials, TEFLON® (polytetrafluoroethylene), TEFLON® coated DACRON®, porous polyurethane, silicone, expanded polytetrafluoroethylene, and expanded polyurethane. It is preferred that all of the foregoing materials be porous to allow for

an intimal layer to form on the tubes. Each of the tubes are connected to expandable and deformable tubular members, or stents. These stents can be similar in structure to those described in disclosed in U.S. Patents 4,733,665 issued on March 29, 1988; U.S. Patent 4,739,762, issued on April 26, 1988; and U.S. Patent 4,776,337 issued
5 on October 11, 1988, all of the foregoing patents being in the name of Julio C. Palmaz, each of which is incorporated herein by reference. Each of the tube/stent structures are then disposed on the end of a balloon catheter. Either both tubes are inserted into the same femoral artery or one of the tubes is inserted into one femoral artery of the patient and the other tube is inserted into the other femoral artery of the
10 patient. Thereafter the tubes are intraluminally delivered to the aorta, thereby disposing at least a portion of each tube within the abdominal aortic aneurysm. The balloons on the distal ends of the catheters are then expanded to expand and deform the tubular members, to force the tubular members radially outwardly into contact with the aorta and each other. This secures the tubular members and a least a portion
15 of each tube within the aorta, whereby the tubes provide a bilateral fluid passageway through the abdominal aortic aneurysm.

While the above mentioned devices would seem to work well, there is a desire to improve upon the device. More particularly, there was a need to ensure that most
20 of the blood flowing through the abdomen flows through the bilateral fluid passageways and not around them where it could cause further damage. The precursor stent gasket described in commonly assigned European Patent Application EP 0947179, filed on March 29, 1999, European Patent Application EP 1000590 (A1), filed on November 8, 1999, and pending U.S. Patent Application Serial No.
25 09/404,660 filed on September 24, 1999, the disclosures of which are hereby incorporated herein by reference, limits the amount of blood which could leak around the bilateral fluid passageways and into the aneurysm. The precursor stent gasket is positioned within the infrarenal neck, between an abdominal aortic aneurysm and the renal arteries, of a patient to assist in repairing the abdominal aortic aneurysm. The
30 stent is designed to be coupled to the bilateral grafts for directing blood flow. The graft has a distal end for positioning distal to the aneurysm, and a proximal end for positioning proximal to the aneurysm. The precursor stent gasket includes a substantially cylindrical expandable member having a proximal end, a distal end and

an interior. The stent gasket further includes a compressible gasket member located within the interior of the expandable member and attached thereto. The compressible member is substantially impervious to blood when in a compressed state and is coupled the graft. This is so the coupled device can direct blood flow through the graft, with the gasket member substantially preventing blood from flowing into the aneurysm.

While the above described devices are large improvements over the prior art, there has been a need for improvement. There has been a desire to have a better device for attaching the graft material to the grafts used in the above described devices. There has been a desire to have an improved stent gasket member for better attachment of the stent gasket member to aortic wall. There has been a desire to have a mechanism for ensuring that the stent gasket member is not prematurely deployed. There has been a desire to improve the design of the stent grafts to make them perform better. Lastly, there has been a desire to improve the grafts on the stent grafts themselves to make them perform better during deployment. The following described invention provides such an improved device.

SUMMARY OF THE INVENTION

In accordance with the present invention there is provided a hollow substantially cylindrical radially expandable stent having proximal and distal open ends and a longitudinal axis extending therebetween. The is for deployment within a human body vessel, and is particularly useful in the manufacture of stent grafts. The stent includes a plurality of hoops comprising a plurality of interconnected struts. The stent has a proximal end hoop and a distal end hoop wherein the distal end hoop and the proximal end hoop have greater radial and longitudinal strength than the hoops therebetween. The stent further includes a plurality of sinusoidal rings connecting adjacent hoops to one another.

BRIEF DESCRIPTION OF DRAWINGS

The foregoing and other aspects of the present invention will best be appreciated with reference to the detailed description of the invention in conjunction
5 with the accompanying drawings, wherein:

Figure 1 is a perspective view of a precursor stent (shown without the gasket, in an expanded state) made in accordance with the present invention.

10 Figure 2 is a view similar to that of figure 1 but including a gasket member made in accordance with the present invention.

Figure 3 is a cross-sectional view of the precursor stent of Figure 2 taken along section line 3-3 of Figure 2.
15

Figure 4 is a side elevational view of an endograft stent prior to the application of the graft material and shown in an expanded state.

Figure 5 is a side elevational view of a longitudinally pleated graft to be used
20 in conjunction with the stent of Figure 4 wherein the pleats are discontinuous.

Figure 6 is a partial side elevational view of another embodiment of the graft wherein the longitudinal pleats are interrupted by circumferential pleats.

25 Figure 7 is an end elevational view of the graft as taken along view line 7-7 of Figure 5, the broken line work representing the graft in a compressed state.

Figure 8 is a side elevational view of a complete stent-graft assembly shown in a deployed state.
30

Figure 9 is an enlarged partial plan view of an attachment tab at the cranial end of the stent as shown in the encircled area of Figure 4.

Figure 10 is a partial, exploded cross-sectional view of the attachment tab as taken along section line 10-10 of Figure 9 and includes a staple and a portion of the graft material prior to affixing the graft to the stent.

5 Figure 11 is a partial cross-sectional view of the attachment means after crimping the staple.

Figure 12 is an enlarged partial plan view of an attachment node at the caudal end of the stent as shown in the encircled area of Figure 4.

10

Figure 13 is a partial, exploded cross-sectional view of the attachment node as taken along section line 13-13 of Figure 12 and includes a staple and a portion of the graft material prior to affixing the graft to the stent.

15 Figure 14 is a partial cross-sectional view of the attachment means after crimping the staple.

Figure 15 is a partial, exploded perspective view of the caudal end of the stent-gasket, or endograft, and a portion of the delivery system shown after its
20 release from the delivery system.

Figures 16, 17 and 18 are sequential schematic perspective views showing the method of positioning and deploying the stent-grafts, or endografts, after the precursor stent has already been deployed.

25

Figure 19 is an elevational view of a fully deployed abdominal aortic repair system made in accordance with the present invention.

Figure 20 is a top plan view of the precursor stent as seen along view line 20-20 of Figure 19.
30

Figure 21 is a photomicrograph of the gasket material prior to substantial cell ingrowth, as taken along section line 21-21 of Figure 3.

Figure 22 is a photomicrograph of the gasket material after substantial cell ingrowth, or biofusion, has taken place as taken along line 22-22 of Figure 19.

Figure 23 is an elevational view of a delivery system for a stent gasket made
5 in accordance with the present invention, wherein the delivery system is inserted into an abdominal aortic aneurysm.

Figure 24 is a view similar to that of figure 23 but showing the stent gasket partially deployed from its delivery system.

10

Figure 25 is a view similar to that of figure 24 but showing the stent gasket fully deployed from its delivery system.

DETAILED DESCRIPTION OF THE INVENTION

15

One preferred use of the present invention is to treat abdominal aortic aneurysms. A better understanding of the present device and its use in treating abdominal aortic aneurysms will be achieved by reading the following description in conjunction with the above incorporated references. In addition, the terms cranial
20 and distal, will refer to the direction towards the head of the patient, and the terms caudal or proximal will refer to the direction away from the head of the patient.

Referring now to the drawings wherein like numerals indicate the same element throughout the views, there is shown in Figure 1 a precursor stent 10, shown
25 in Figure 1. As will be discussed below, stent 10 is to be deployed within the infrarenal neck, between an abdominal aortic aneurysm and the renal arteries of a patient to assist in repairing the abdominal aortic aneurysm. The stent is designed to be coupled to one or more stent grafts for directing blood flow through the aneurysm. The stent includes a substantially cylindrical self-expanding member 12
30 made from a plurality of interconnected struts. Member 12 having two open ends, a proximal end 14, a distal end 16, and a longitudinal axis extending therebetween and an interior 18. The precursor stent further includes at least two, but preferably 8 as shown in Figure 1, spaced apart longitudinal legs 20 each having proximal and distal

ends 24 and 26 respectively. Preferably, there is a leg extending from each apex 11 of diamonds 13 (such diamonds being formed by the struts). The distal ends 26 of the legs are attached to the proximal end 14 of the member 12, the legs extending proximally away from the member. At least one, but preferably each leg includes a flange 28 adjacent its proximal end which, as is described in greater detail below, allows for the stent to be retrieved into its delivery apparatus after partial or full deployment of member 12 so that it can be turned, or otherwise repositioned for proper alignment.

The self expanding stents described herein are preferably made from superelastic Nickel Titanium alloys (Nitinol). Descriptions of medical devices which use such alloys can be found in U.S. Patents 4,665,906 issued to Jervis on May 19, 1987, and European Patent Application EP 0928606 filed on January 8, 1999, both of which are hereby incorporated herein by reference. Stent 10 is preferably laser cut from a tubular piece of Nickel Titanium Alloy and thereafter treated so as to exhibit superelastic properties at body temperature. Stent 10 is shown in the figures as being a diamond patterned stent, having approximately 8 diamonds, and when the stent is fully expanded the diamonds would have angles of 45-55 degrees at their distal and proximal ends. However, stent 10 can take on many different patterns or configurations.

In one embodiment of precursor stent 10, shown in most of the figures but removed from Figure 1 for clarity, precursor stent 10 further includes a gasket member 30 (thereby forming a stent gasket or stent graft). This feature can be better understood by referring to Figures 2 and 3. As seen from those figures, precursor stent 10 further includes a gasket member 30. Gasket member 30 surrounds the member 12 and can be located along the interior of member 12, the exterior of member 12 or both. The gasket member helps impede any blood trying to flow around the stent grafts, described below, after they have been inserted (as shown in Figure 19) and from flowing around the precursor stent itself. For this embodiment gasket member 30 is a compressible member located along both the interior and the exterior of expandable member 12.

Gasket member 30 can be made from any number of materials known to those skilled in the art. Preferably, gasket member 30 is made from an open cell polyurethane foam, however other flexible foams could be used, such as polyethylene, polytetrafluoroethylene, other various polymer materials which are woven or knitted to provide a flexible structure such as Dacron, polyurethane, polypropylene, polytetrafluoroethylene can also be used. Preferably, the polyurethane foam has a cell size of 50-100 pores per inch, and the density of the foam is 1.5-3.5 pounds per cubic foot. Foams having these qualities absorb the blood like a sponge, contributing to blood stagnation which leads to thrombosis. In addition, it provides a trellis for cellular infiltration, and eventually scaffolds tissue incorporation. This helps to better anchor the device within the body, thereby preventing stent migration. An example of such a foam is shown in the photograph of figure 21. Figure 21 shows a scanning electron microscope of a open cell polyurethane foam having approximately 200-500 micrometer pores.

This ability of the tissue from the artery wall to incorporate the open-pore foam structure has been termed by assignee as "Biofusion". This tissue incorporation effect can best seen by referring to photographs 21 and 22. Figure 22 shows histological photographs of connective tissue infiltrating and healing into the gasket member 30 upon a 1 month follow-up of a device implanted into a target vessel. This ability of the tissue to heal into the foam creates a long term stable biological interface which, upon about six weeks after implantation, cannot be separated from the tissue without tearing the foam material. The "Biofusion" effect has many advantages. It has the potential to obviate late endo-leakage by preventing areas of non-organized clot from being displaced or recanalized. It is also believed that "Biofusion" creates a connective tissue collar around the gasket that would prevent the aortic neck from dilating over time. Restriction of neck dilation avoids endoleakage paths and implant migration that can be caused by an insufficient fit with the aorta. The use of such above described foams on stent grafts is not limited to abdominal aortic aneurysm repair, but could be applied in many stent graft applications such as other aneurysm repair and vessel malformation and occlusion.

The foams described above are preferably highly compressible, so as to keep the crimped profile low for better delivery. In addition, it is preferable that the gasket member be substantially impervious to the flow of blood, at least when in a partially compressed state. When used throughout for the present invention, materials which are substantially impervious to the flow of blood include materials which become substantially impervious to the flow of blood after being saturated with blood. When the stent tubes and graft members, described below, are inserted and expanded within the gasket 30, the gasket 30 will compress. In this state, the gasket should be substantially impervious to blood so as to prevent blood from flowing through the interior 18 of member 12 and into the aneurysm. Gasket 30 can be attached to expandable member 12 by any number of means including polyurethane glue, a plurality of conventional sutures of polypropylene, DACRON®, or any other suitable material and attached thereto. Other methods of attaching gasket 30 to expandable member include adhesives, ultrasonic welding, mechanical interference fit and staples.

15

As seen from Figure 2, stent 10 preferably includes a number of radiopaque markers 15. As shown, markers 15 are coils of radiopaque metal, wrapped around the struts of the stent. The markers are positioned along the stent so that the physician can better know the exact position of the stent during deployment when viewed under fluoroscopy. Markers 15 are preferably made from 0.010" diameter tantalum (Ta) wire wrapped tightly around the struts. Three markers are used; two near the distal end of the device, and one proximal thereto. The distal two are 180° apart, and the proximal one is equally spaced between the distal two when viewed from a rotation where the top two are spaced as far apart as possible. This proximal marker then aids proper rotational positioning of the device. Specifically, one of the distal markers is 5 mm long and is adjacent to the aperture 34 in the gasket; the other is 2 mm long and is adjacent to the hole 36. Since hole 36 should be placed adjacent to the right side of the aneurysm, as shown in figure 19, the small distal marker should be placed on the right side; the proximal marker (also 2 mm long) should appear fluoroscopically to be midway between the upper two markers.

30

As seen from figures 2 and 3, the precursor stent further includes an occlusive member 32 attached to member 12. The occlusive member covers at least a portion of the interior of the expandable member. The occlusive member covers the interior of member 12 in such a way that a lumen 5 of the expandable member which provides passageway from its proximal end 14 to its distal 16 is at least partially blocked. Occlusive member 32 further includes two openings 34 and 36 extending therethrough. Opening 34 is relatively small and is designed to receive a guidewire, wherein such guidewire helps deliver stent 10 to the target site. Opening 36 is relatively large, and is designed to receive another guidewire having a loaded stent graft proximal thereto. As will be explained below, the occlusive member helps to ensure proper side by side placement of the two stent grafts.

Precursor stent 10 acts to temporarily scaffold the gasket member within the body, until the stent grafts are deployed (see figure 19). Shown in figure 4 is a preferred embodiment of a stent 40 for use in a stent graft in accordance with the present invention. Stent 40 is made from a plurality of interconnected struts 44, and has an interior surface 41 and an exterior surface 43 (shown in figure 15). Figure 4 shows stent 40 in its fully deployed, un-crimped state. As will be appreciated by those skilled in the art, stent 40 should be crimped to a smaller diameter prior to insertion into a patient. Stent 40 is preferably made from superelastic Nitinol, and have enough outward force to stay within the body, without the use of the precursor stent 10. Stent 40 is preferably made from a single tube of Nitinol, having the following features laser cut therein. Stent 40 has a number of hoops 42 comprising a number of struts 44 making a diamond shape configuration, wherein each hoop preferably has 9 diamonds. Stent 40 further includes a number of sinusoidal rings 50 for connecting adjacent hoops to one another. The sinusoidal rings are made from a number of alternating struts 52, wherein each ring preferably has 54 struts. As will be explained in detail below in connection with the discussion of figures 9-14, stent 40 includes a distal attachment means 54 and a proximal attachment means 56.

30

Stent 40 has a proximal hoop 48 and a distal hoop 46, also referred to as anchors. The proximal hoop is flared, and is exposed after the graft has been attached thereto. The diamond pattern for the anchors, as well as the other hoops,

provide the hoops with radial and longitudinal stiffness. The longitudinal strength provides for better mechanical fixation of stent 40 to a graft (described below). The radial strength provides the distal hoop 46 with better attachment and sealing to stent gasket 10, and provides the proximal hoop 48 with better fixation and sealing to the arterial wall. In one preferred embodiment, the proximal and distal hoops have greater radial and longitudinal strength than the hoops therebetween. This creates a stent graft having stiff ends for anchoring, but a more flexible body for navigation through the vasculature. The stiffer ends can be accomplished by changing the dimensions of the struts for the end hoops, or by varying the heat treatment of the end hoops during manufacture. The rings allow the stent to bend more easily, and generally provide for more flexibility when the stent is being delivered through a tortuous vessel. When a non-compliant graft is attached to stent 40, the strength of the diamond hoops scaffolds any graft folding into the blood flow lumen, while maintaining a tight kink radius.

As stated above, stent 40 preferably has a graft member attached thereto. The graft member covers at least a portion of the interior or exterior of stent 40, and most preferably covers substantially all of the exterior of the stent 40. Shown in figures 5-7 is an embodiment of a tubular graft 60 for use with the present invention. Graft member 60 can be made from any number of materials known to those skilled in the art, including woven polyester, Dacron, Teflon or polyurethane. Graft 60 has a proximal end 64, a distal end 62, and a longitudinal axis 66 extending therebetween. As seen from figure 5, graft 60 has a plurality of longitudinal pleats 68 extending along its surface, and being generally parallel to longitudinal axis 66. As seen from figure 7, when the graft 60 is collapsed around its center, much as it would be when it is delivered into a patient, the pleats in the graft come together as a series of radially oriented regular folds which pack together efficiently, so as to minimize wrinkling and other geometric irregularities. Upon subsequent expansion, graft 60 assumes its natural cylindrical shape, and the pleats or folds uniformly and symmetrically open.

The pleats provide for a more uniform crimping of the graft 60, which helps the assembled stent graft (stent 40 attached to graft 60, as will be discussed below) to crimp into a relatively low profile delivery system, and provides for a controlled and

consistent deployment therefrom. In addition, pleats 68 help facilitate stent graft manufacture, in that they indicate the direction parallel to the longitudinal axis, allowing stent to graft attachment along these lines, and thereby inhibiting accidental twisting of the graft relative to the stent after attachment. The force required to push
5 the stent-graft out of the delivery system may also be reduced, in that only the pleated edges of the graft make frictional contact with the inner surface of the delivery system. One further advantage of the pleats is that blood tends to coagulate generally uniformly in the troughs of the pleats, discouraging asymmetric or large clot formation on the graft surface, thereby reducing embolus risk.

10

In one preferred embodiment, the depths of pleats 68 range from 0.06 inch to 0.07 inch for a graft having a crimped inner diameter of 0.08 inch and a crimped outer diameter ranging from 0.131 inch to 0.155 inch. This combination of pleat depth and inner and outer diameters results in pleat frequencies that generally
15 preclude the existence of excessive radial graft flaps across the range of diameters for the device

15

As seen best from Figure 6, graft 60 preferably includes a plurality of radially oriented pleat interruptions 70. The pleat interruptions are substantially circular and
20 are oriented perpendicular to longitudinal axis 66. While the pleats 68 mentioned above provide for a uniform crimping of graft 60, they may tend to increase kink propensity since they run perpendicular to the graft's natural folding tendencies when bent along its axis. Pleat interruptions 70 allow the graft to better bend at selective points. This design provides for a graft that has good crimpability and improved kink
25 resistance.

20

25

Figure 9 shows an up-close view of distal attachment means 54 of stent 40. Distal hoop 46 of stent 40 has a plurality of attachment tabs 82 extending therefrom which are formed from the joining together of two struts 44(a) and 44(b).
30 Attachment means 54 comprises two apertures 84 (first aperture) and 86 (second aperture) extending therethrough. As seen from figure 10, graft 60 also preferably includes two apertures 74 and 76 (which can be initially created during the attachment process) which are coextensive with apertures 84 and 86 when graft 60 is

30

placed over stent 40 for attachment. Finally, stent-graft 80 includes a staple 90 having a crown 92 and attachment legs 94 (first leg) and 96 (second leg) extending therefrom. Attachment leg 96 extends through apertures 76 and then aperture 86. Simultaneously, leg 94 bends around notch 85, but it does not penetrate graft 60 like
5 leg 96. Thereafter, attachment leg 94 and 96 are bent back through apertures 84 and 74 and in towards crown 92, so as to attach the distal end of the graft to the distal end of the stent as shown in Figure 11. Legs 94 and 96 make contact with crown 92 after attachment. Preferably, there are six staples at the distal end.

10 Figure 12 shows an up-close view of proximal attachment means 56 of stent 40. Proximal hoop 48 of stent 40 has a plurality of members 110 occurring at the joining of four struts 44(c)-44(f). Attachment means 56 comprises three apertures 112 (first aperture), 114 (middle aperture) and 116 (second aperture) extending therethrough. As seen from figure 13, graft 60 also preferably includes three
15 apertures 121, 123 and 125 (which can be initially made during the attachment process by puncturing therethrough with a staple) which are coextensive with apertures 112, 114 and 116 when graft 60 is placed over stent 40 for attachment. Finally, stent-graft 80 includes a staple 120 having a crown 122 and legs 124 (first leg) and 126 (second leg) extending therefrom. Legs 124 and 126 extend through
20 apertures 112 and 116 and then through apertures 121 and 125 respectively. Thereafter, legs 124 and 126 are bent back through apertures 124 and 114 and in towards crown 122, so as to attach the proximal end of the graft to the proximal end of the stent as shown in figure 14. Legs 124 and 126 make contact with crown 122 after attachment. Preferably, there are three staples at the proximal end.

25 The above staple aperture design has many advantages for attaching a stent to a graft. Because the legs of the staple are folded around and imbedded within a pocket or the like, any risk of puncturing an inflation balloon is minimized. In addition, the structural integrity of the stent-graft is believed to be increased in that
30 these staples should more securely attach the graft to the stent compared to prior art designs which use suture or adhesives to attach the graft to the stent. Staples 90 and 120 can be made from any number of materials known in the art, including tantalum alloys, platinum alloys or stainless steel, such as 316 LVM stainless steel. The staples

may take on other configurations and shapes, and can be coated for lubricity purposes. Having the staples made from a radiopaque material helps the physician in accurately deploying the device.

5 Another feature of stent-graft 80 can be better understood by referring to its delivery apparatus 130 shown in Figure 15. Apparatus 130 is very similar to other self-expanding delivery apparatus described in the above incorporated references. Apparatus 130 includes an outer sheath 132 which is essentially an elongated tubular member, similar to ordinary guiding catheters which are well known to those of
10 ordinary skill in the art. An example of a particularly preferred outer sheath is described in commonly assigned U.S. Patent 6,019,778 issued on February 1, 2000, which is hereby incorporated herein by reference. Sheath 132 has a distal end 134 and a proximal end (not shown). Apparatus 130 also includes an inner shaft 140 located coaxially within the outer sheath 132 prior to deployment. The inner shaft
15 has a distal end 142 and a proximal end (not shown). The distal end 142 of the shaft has at least two grooves 144 disposed thereon. Stent 40 preferably has a number of flanges 41 disposed at its proximal end. The flanges on the stent are set within the grooves of the inner shaft, thereby releasably attaching the stent to the inner shaft. The delivery system for precursor stent 10 is also similar, having an outer sheath and
20 an inner shaft wherein the shaft has grooves to receive flanges 28 of precursor stent 10.

The advantages of flanges 41 on stent 40 and flanges 28 on precursor stent 10 and the grooves on the inner shafts of their delivery system is that they may allow for
25 partial deployment of the stents and recapture within the delivery apparatus if the physician is not pleased with the position of the stent. The present invention allows the physician to partially deploy one of the stents (10 or 80) while the flanges remain within the sheath. The flange groove combination allows the physician to “pull” the stent back into the delivery device if the placement is not optimal.

30

The advantages of flanges 28 on stent 10 and the grooves on the inner shafts of their delivery system can best be described by referring to figures 23-25. Figure 23 shows the delivery apparatus 300 for stent gasket 10. Apparatus 300 is very

similar to other self-expanding delivery apparatus described in the above incorporated references. Apparatus 300 includes an outer sheath 332 which is essentially an elongated tubular member, similar to ordinary guiding catheters which are well known to those of ordinary skill in the art. An example of a particularly preferred
5 outer sheath is described in commonly assigned U.S. Patent 6,019,778 issued on February 1, 2000, which is hereby incorporated herein by reference. Apparatus 300 also includes an inner shaft 340 located coaxially within the outer sheath 332 prior to deployment. Inner shaft 334 includes a number of grooves 344. As seen from Figure 24, this arrangement allows for partial deployment of stent 10 and recapture within
10 the delivery apparatus if the physician is not pleased with the initial position of the stent. The present invention allows the physician to partially deploy stent 10 while the flanges remain within the sheath. The flange groove combination allows the physician to "pull" the stent back into the delivery device if the placement is not optimal.

15

In order to prevent the physician from prematurely completely deploying the stent 10, a releasable stop 350 is preferably placed on the inner shaft. The stop could be a ring having a greater diameter than the sheath, so that as the sheath is pulled proximally along the inner shaft it hits the stop, and prevents full deployment of the
20 entire stent 10. The stop is preferably releasably attached to the inner member so that it can be released from its engagement with the inner shaft to allow the outer member to slide back enough to fully deploy the entire stent 10 within the body.

Figures 16-18 generally show how the above described invention is deployed
25 within the body. Prior to what is shown in Figure 16, the physician would first insert the precursor stent 10, having the gasket member attached thereto, into the body with the aid of guidewire 200, which remains in the body after deployment. The stent gasket is delivered through one of the patient's femoral arteries and into a first iliac artery 1 and deployed within the infrarenal neck 3. Thereafter, the delivery device for
30 the precursor stent is removed, without removing guidewire 200, and another guidewire 202 is inserted through the other femoral artery and into the other iliac artery 2. Because the size of opening 36 in occlusive member 32 is relatively large, the physician can only maneuver guidewire 202 therethrough. Thereafter stent-graft

delivery apparatus 132(a) and 132(b) are inserted into femoral arteries 1 and 2 by sliding them over guidewires 200 and 202, and accurately delivering them to the target site. Thereafter, both stent grafts 80(a) and 80(b) are either separately or simultaneously deployed within the body. Ultimately the distal ends of the stent grafts reside level with each other, just below the renal arteries, and some distance above the distal end of the stent gasket. The bodies of the stent grafts pass through the stent gasket and through the aneurysm sac.

After properly delivery, precursor stent 10 and stent grafts 80(a) and 80(b) should appear as they do in figure 19. Precursor stent 10 along with its attached gasket member 30 are firmly secured within the infrarenal neck 300. The outward force of the stent grafts 80 on the precursor stent 10 help to secure the device within the body. The proximal ends of the stent-grafts are firmly attached to the iliac arteries 1 and 2. Thereafter blood will flow from the abdominal aorta 302 down into and through stent grafts 80(a) and 80(b) and into iliac arteries 1 and 2, thereby bypassing the aneurysmal sack 304. If all the components are placed accurately, distal end of the device should appear as it does in Figure 20.

In order to prevent the physician from prematurely completely deploying the stent 10, a releasable stop is preferably placed on the inner shaft. The stop could be a ring having a greater diameter than the outer member, so that as the outer member is pulled proximally along the inner shaft it hits the stop, and prevents full deployment of the entire stent 10. The stop is preferably releasably attached to the inner member, by threads, snap fit or the like, so that it can be released from its engagement with the inner shaft to allow the outer member to slide back enough to fully deploy the entire stent 10 within the body.

Although particular embodiments of the present invention have been shown and described, modification may be made to the device and/or method without departing from the spirit and scope of the present invention. The terms used in describing the invention are used in their descriptive sense and not as terms of limitations.

WHAT IS CLAIMED IS:

1. An hollow substantially cylindrical radially expandable stent having proximal and distal open ends and a longitudinal axis extending therebetween, said stent for deployment within a human body vessel, said stent comprising:
 - a. a plurality of hoops comprising a plurality of interconnected struts, said stent having a proximal end hoop and a distal end hoop wherein said distal end hoop and said proximal end hoop have greater radial and longitudinal strength than the hoops therebetween; and
 - b. a plurality of sinusoidal rings connecting adjacent hoops to one another.
2. The stent according to claim 1 wherein said struts forming said hoops are arranged so as to create a diamond pattern on said hoops.
3. The stent according to claim 1 wherein said stent is a self expanding stent.
4. The stent according to claim 3 wherein said stent is made from a superelastic nickel titanium alloy.
5. The stent according to claim 1 wherein at least one of said distal and proximal hoops is flared so as to have a larger diameter than a hoop adjacent thereto.

6. A stent graft for deployment within a human body vessel, said stent comprising:

a. wherein said graft member is selected from a group of materials comprising: Dacron, Teflon, woven polyester, and polyurethane.

b. a hollow substantially cylindrical radially expandable stent, having proximal and distal open ends and a longitudinal axis extending therebetween, said stent having an interior and an exterior, said stent comprising a plurality of hoops comprising a plurality of interconnected struts, said stent having a proximal end hoop and a distal end hoop wherein said distal end hoop and said proximal end hoop have greater radial and longitudinal strength than the hoops therebetween, said stent further including a plurality of sinusoidal rings connecting adjacent hoops to one another; and

c. a graft member attached to said body.

7. The stent graft according to claim 6 wherein said struts forming said hoops are arranged so as to create a diamond pattern on said hoops.

8. The stent graft according to claim 6 wherein said stent is a self expanding stent.

9. The stent graft according to claim 8 wherein said stent is made from a superelastic nickel titanium alloy.

10. The stent graft according to claim 6 wherein at least one of said distal and proximal hoops is flared so as to have a larger diameter than a hoop adjacent thereto.

11. The stent graft according to claim 7, wherein said graft member covers substantially all of said exterior surface of said stent.

12. The stent graft according to claim 7 wherein said stent is a self expanding stent.

13. The stent graft according to claim 9 wherein said stent is made from a superelastic nickel titanium alloy.

14. The stent graft according to claim 7 wherein said graft member is selected
5 from a group of materials comprising: Dacron, Teflon, woven polyester, and polyurethane.

15. The stent graft according to claim 7 wherein said tab further includes a notch
at an end most portion of said tab, wherein said second leg of said staple abuts
10 against and bends around said notch.

16. The stent graft according to claim 1 wherein said staple is radiopaque.

17 A stent graft for insertion into a body lumen in order to repair said lumen,
15 said stent graft comprising:

a. a substantially cylindrical hollow expandable stent comprising a
plurality of interconnected struts, said stent having a distal end and a
proximal end, and an interior surface and an exterior, at least one of
20 said struts having adjacent first, second and middle apertures
extending therethrough;

b. a graft member covering a predetermined portion of least one of said
interior surface and said exterior surface;

25 c. a staple for attaching said graft member to said stent, said staple
comprising a crown and first and second legs extending therefrom,
said first leg extending through said graft material and through said
first aperture, said second leg extending through said graft material
30 and through said second aperture, both of said legs being bent
towards said crown such that they extend through said middle
aperture.

18. The stent graft according to claim 14, wherein said graft member covers substantially all of said exterior surface of said stent.

5 19. The stent graft according to claim 14 wherein said stent is a self expanding stent.

20. The stent graft according to claim 16 wherein said stent is made from a superelastic nickel titanium alloy.

10 21. The stent graft according to claim 14 wherein said graft member is selected from a group of materials comprising: Dacron, Teflon, woven polyester, and polyurethane.

15 22. The stent graft according to claim 14 wherein said staple is radiopaque.

ABSTRACT OF THE DISCLOSURE

In accordance with the present invention there is provided a stent graft for insertion into a body lumen, such as a blood vessel, in order to repair such lumen.

- 5 The stent graft includes a substantially cylindrical hollow expandable stent comprising a plurality of interconnected struts. The stent has a distal end and a proximal end, and an interior surface and an exterior surface. At least one strut of the stent has first and second apertures extending therethrough from the interior surface to the exterior surface. The stent graft also includes a graft member covering a predetermined
- 10 portion of least one of the interior surface and the exterior surface of the stent. In addition, the stent graft further includes a staple for attaching the graft member to the stent. The staple has a crown and two legs extending therefrom. At least one of the legs of the staple extends through the graft material and through the first aperture. Both of the legs are bent inwardly towards said crown such that they evert back and
- 15 extend through the second aperture.

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13





FIG. 14






FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22



FIG. 23




FIG. 24






FIG. 25



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

AN IMPROVED STENT FOR USE IN A STENT GRAFT

the specification of which

(check one) ☒ [X] is attached hereto.

☐ [] was filed on _____ as

Application Serial No. _____

and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.

Filing Date

Status

Application Serial No.

Filing Date

Status


I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith as well as to file equivalent patent applications in countries foreign to the United States including the filing of international patent applications in accordance with the Patent Cooperation Treaty: Audley A. Ciamporcero, Jr. (Reg. #26,051), Steven P. Berman (Reg. #24,772), Andrea L. Colby (Reg. #30,194), Michael Stark (Reg. #32,495), Dean L. Garner (Reg. #35,877), Verne E. Kreger, Jr., (Reg. #35,231), Matthew S. Goodwin (Reg. #32,839) Bernard E. Shay (Reg. #32,061), E. Richard Skula, (Reg. No. 31,061), William K. Wissing (Reg. No. 34,757) One Johnson & Johnson Plaza, New Brunswick, NJ 08933.

Address all telephone calls to Dean L. Garner at telephone no. (513) 337-8559.

Address all correspondence to Audley A. Ciamporcero, Jr., One Johnson & Johnson Plaza,
New Brunswick, NJ 08933-7003.

I hereby declare that all statements made herein of my own knowledge are true and that all
statements made on information and belief are believed to be true; and further that these
statements were made with the knowledge that willful false statements and the like so made are
punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United
States Code and that such willful false statements may jeopardize the validity of the application
or any patent issued thereon.

Inventor's Signature:
Full Name of Sole
or First Inventor


Frank Butaric

Date: 10/23/00

Citizenship: USA
Residence: 12915 NW 22nd Manor, Pembroke Pines, FL 33028
Post Office Address: Same as above


Inventor's Signature:
Full Name of Second Joint
Inventor, If Any

Bill K. Ng

Date: _____

Citizenship: USA
Residence: 1138 Plum Avenue, Sunnyvale, CA 94087
Post Office Address: Same as above

Inventor's Signature:
Full Name of Third Joint
Inventor, If Any


Marc Ramer

Date: 10-19-00

Citizenship: USA
Residence: 1460 Garden Road, Weston, FL 33326
Post Office Address: Same as above

Address all correspondence to Audley A. Ciamporcero, Jr., One Johnson & Johnson Plaza,
New Brunswick, NJ 08933-7003.

I hereby declare that all statements made herein of my own knowledge are true and that all
statements made on information and belief are believed to be true; and further that these
statements were made with the knowledge that willful false statements and the like so made are
punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United
States Code and that such willful false statements may jeopardize the validity of the application
or any patent issued thereon.


Inventor's Signature:
Full Name of Sole
or First Inventor

Frank Butaric

Date: _____

Citizenship: USA
Residence: 12915 NW 22nd Manor, Pembroke Pines, FL 33028
Post Office Address: Same as above

Inventor's Signature:
Full Name of Second Joint
Inventor, If Any



Bill K. Ng

Date: Oct. 11 . 2000

Citizenship: USA
Residence: 1138 Plum Avenue, Sunnyvale, CA 94087
Post Office Address: Same as above

Inventor's Signature:
Full Name of Third Joint
Inventor, If Any

Marc Ramer

Date: _____

Citizenship: USA
Residence: 1460 Garden Road, Weston, FL 33326
Post Office Address: Same as above

Inventor's Signature:
Full Name of Fourth Joint
Inventor, If Any




Dieter Stoeckel

Date: 13 Oct 2000

Citizenship: Germany
Residence: 960 Black Mountain Court, Los Altos, CA 94024
Post Office Address: Same as above

Inventor's Signature:
Full Name of Fifth Joint
Inventor, If Any




Gregory Mast

Date: 13 Oct 2000

Citizenship: USA
Residence: 36281 Larch Way, Fremont, CA 94536
Post Office Address: Same as above

Inventor's Signature:
Full Name of Sixth Joint
Inventor, If Any



Luis A. Davila

Date: 13 Oct 2000

Citizenship: USA
Residence: 3527 Ballantyne Drive, Pleasanton, CA 94588
Post Office Address: Same as above

Inventor's Signature:
Full Name of Seventh Joint
Inventor, If Any

Kenneth S. Solovay

Date: _____

Citizenship: USA
Residence: 16732 Diamond Drive, Ft. Lauderdale, FL 33331
Post Office Address: Same as above

Inventor's Signature:
Full Name of Fourth Joint
Inventor, If Any

Dieter Stoeckel

Date: _____

Citizenship: Germany
Residence: 960 Black Mountain Court, Los Altos, CA 94024
Post Office Address: Same as above

Inventor's Signature:
Full Name of Fifth Joint
Inventor, If Any

Gregory Mast

Date: _____

Citizenship: USA
Residence: 36281 Larch Way, Fremont, CA 94536
Post Office Address: Same as above


Inventor's Signature:
Full Name of Sixth Joint
Inventor, If Any

Luis A. Davila

Date: _____

Citizenship: USA
Residence: 3527 Ballantyne Drive, Pleasanton, CA 94588
Post Office Address: Same as above

Inventor's Signature:
Full Name of Seventh Joint
Inventor, If Any


Kenneth S. Solovay

Date: 10-23-06

Citizenship: USA
Residence: 16732 Diamond Drive, Ft. Lauderdale, FL 33331
Post Office Address: Same as above